Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMI2012 Vaccine Against COVID-19 Variant in Healthy Adults
NCT07791186Phase 1Not yet recruiting
- Sponsor
- BMI OrganBank
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMI2012 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by BMI OrganBank. Primary endpoint: Incidence of Adverse Events Following Investigational Product Administration at Day 28. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BMI2012
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07791186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791186.